Ghana Approves Moxidectin as First River Blindness-Endemic Country
• Ghana's FDA has approved moxidectin 2mg oral tablets for treating river blindness in adults and children aged 4 and older, marking a significant step in disease elimination.
• The MOMENTUM pilot program, set to begin in January 2025 in the Twifo Atti-Morkwa district, will implement community treatment using moxidectin.
• Moxidectin reduces skin microfilariae levels more effectively than ivermectin, potentially accelerating the elimination of parasite transmission.
• This approval marks the first registration of moxidectin in a country heavily affected by neglected tropical diseases, achieved by a not-for-profit company.
© Copyright 2025. All Rights Reserved by MedPath